Bumgardner, G L <br/><br/>
Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.  [electronic resource] 

 -  Transplantation  Sep 2001 
 - 839-45 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0041-1337 
<br/><br/><label>Standard No.: </label>10.1097/00007890-200109150-00017  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Disease<br/>Adrenal Cortex Hormones--administration & dosage<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Azathioprine--administration & dosage<br/>Cyclosporine--administration & dosage<br/>Daclizumab<br/>Graft Rejection--prevention & control<br/>Graft Survival<br/>Humans<br/>Immunoglobulin G--adverse effects<br/>Immunosuppressive Agents--adverse effects<br/>Kidney Transplantation--adverse effects<br/>Lymphoproliferative Disorders--etiology<br/>Neoplasms--etiology<br/>Receptors, Interleukin-2--antagonists & inhibitors<br/>Survival Rate<br/>Time Factors